Reviewing PSA levels among statin users screened in the Finnish Prostate Cancer Screening Trial, researchers from Helsinki found a decrease in prostate cancer incidence in this group, compared to those who did not take the drugs.
A significant decrease was found in the incidence of T3 cancers and thos with a Gleason score ranging 5-6. Researchers also found lower serum PSA levels and free/total PSA ratios in this population.
Non-statin, lipid-lowering drugs were not associated with incidence, stage or grade.